OBJECTIVE: The objective of this study was to compare robotic-prostatectomy plus adjuvant radiation therapy (RPRAT) versus primary RT for high-risk prostate cancer (HRPCa).
MATERIALS AND METHODS: A retrospective chart review was performed for the HRPCa patients treated in our institution between 2000 and 2010. One hundred and twenty-three patients with high-risk disease were identified. The Chi-square test and Fisher's exact test were used to compare local control and distant failure rates between the two treatment modalities. For prostate-specific antigen comparisons between groups, Wilcoxon rank-sum test was used.
RESULTS: The median follow-up was 49 months (range: 3-138 months). Local control, biochemical recurrence rate, distant metastasis, toxicity, and disease-free survival were similar in the two groups.
CONCLUSIONS: Primary RT is an excellent treatment option in patients with HRPCa, is equally effective and less expensive treatment compared with RPRAT. A prospective randomized study is required to guide treatment for patients with HRPCa.
Written by:
Singh P, Desai P, Arora S, Pham AH, Wernicke AG, Smith M, Nori D, Clifford Chao KS, Parashar B. Are you the author?
Department of Radiation Oncology, Weill Cornell Medical Center, New York, NY 10065, USA.
Reference: J Cancer Res Ther. 2015 Jan-Mar;11(1):191-4.
doi: 10.4103/0973-1482.139601
PubMed Abstract
PMID: 25879360